Immunometabolic control by Klebsiella pneumoniae-Immunometabolism-CSCIED科技核心评价数据库-手机版

Immunometabolic control by Klebsiella pneumoniae

Immunometabolic control by Klebsiella pneumoniae

ES评分 7.6 浏览量：988 下载量：0

DOI	10.1097/IN9.0000000000000028
刊名	Immunometabolism IJ
年，卷(期)	2023, 5(3)
作者	Prince, Alice; Wong Fok Lung, Tania,
作者单位	[Prince, Alice; Wong Fok Lung, Tania] Columbia Univ, Dept Pediat, New York, NY 10027 USA
摘要	Klebsiella pneumoniae is a common Gram-negative pathogen associated with community-acquired and healthcare-associated infections. Its ability to acquire genetic elements resulted in its rapid development of resistance to virtually all antimicrobial agents. Once infection is established, K. pneumoniae is able to evade the host immune response and perhaps more importantly, undergo metabolic rewiring to optimize its ability to maintain infection. K. pneumoniae lipopolysaccharide and capsular polysaccharide are central factors in the induction and evasion of immune clearance. Less well understood is the importance of immunometabolism, the intersection between cellular metabolism and immune function, in the host response to K. pneumoniae infection. Bacterial metabolism itself is perceived as a metabolic stress to the host, altering the microenvironment at the site of infection. In this review, we will discuss the metabolic responses induced by K. pneumoniae, particularly in response to stimulation with the metabolically active bacteria versus pathogen-associated molecular patterns alone, and their implications in shaping the nature of the immune response and the infection outcome. A better understanding of the immunometabolic response to K. pneumoniae may help identify new targets for therapeutic intervention in the treatment of multidrug-resistant bacterial infections.
Abstract	Klebsiella pneumoniae is a common Gram-negative pathogen associated with community-acquired and healthcare-associated infections. Its ability to acquire genetic elements resulted in its rapid development of resistance to virtually all antimicrobial agents. Once infection is established, K. pneumoniae is able to evade the host immune response and perhaps more importantly, undergo metabolic rewiring to optimize its ability to maintain infection. K. pneumoniae lipopolysaccharide and capsular polysaccharide are central factors in the induction and evasion of immune clearance. Less well understood is the importance of immunometabolism, the intersection between cellular metabolism and immune function, in the host response to K. pneumoniae infection. Bacterial metabolism itself is perceived as a metabolic stress to the host, altering the microenvironment at the site of infection. In this review, we will discuss the metabolic responses induced by K. pneumoniae, particularly in response to stimulation with the metabolically active bacteria versus pathogen-associated molecular patterns alone, and their implications in shaping the nature of the immune response and the infection outcome. A better understanding of the immunometabolic response to K. pneumoniae may help identify new targets for therapeutic intervention in the treatment of multidrug-resistant bacterial infections.
关键词	immunometabolism; metabolic reprogramming; Klebsiella pneumoniae; antimicrobial resistance; pulmonary infection; tolerance; resistance
KeyWord	immunometabolism; metabolic reprogramming; Klebsiella pneumoniae; antimicrobial resistance; pulmonary infection; tolerance; resistance
基金项目
页码	1-9

参考文献
相关文献

[1]. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.

[2]. Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18.

[3]. Wyres KL, Wick RR, Judd LM, et al. Distinct evolutionary dynamics of horizontal gene transfer in drug resistant and virulent clones of Klebsiella pneumoniae. PLoS Genet. 2019;15(4):e1008114.

[4]. Karami-Zarandi M, Rahdar HA, Esmaeili H, et al. Klebsiella pneumoniae: an update on antibiotic resistance mechanisms. Future Microbiol. 2023;18:65–81.

[5]. Wyres KL, Lam MMC, Holt KE. Population genomics of Klebsiella pneumoniae. Nat Rev Microbiol. 2020;18(6):344–59.

[6]. Wyres KL, Nguyen TNT, Lam MMC, et al. Genomic surveillance for hypervirulence and multi-drug resistance in invasive Klebsiella pneumoniae from South and Southeast Asia. Genome Med. 2020;12(1):11.

[7]. Vornhagen J, Roberts EK, Unverdorben L, et al. Combined comparative genomics and clinical modeling reveals plasmid-encoded genes are independently associated with Klebsiella infection. Nat Commun. 2022;13(1):4459.

[8]. Bengoechea JA, Sa Pessoa J. Klebsiella pneumoniae infection biology: living to counteract host defences. FEMS Microbiol Rev. 2019;43(2):123–44.

[9]. Kelly B, OʼNeill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771–84.

[10]. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature. 2013;496(7444):238–42.

[11]. Ahn D, Penaloza H, Wang Z, et al. Acquired resistance to innate immune clearance promotes Klebsiella pneumoniae ST258 pulmonary infection. JCI Insight. 2016;1(17):e89704.

[12]. Wong Fok LT, Charytonowicz D, Beaumont KG, et al. Klebsiella pneumoniae induces host metabolic stress that promotes tolerance to pulmonary infection. Cell Metab. 2022;34(5):761–74.e769.

[13]. Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;32(3):e00001–19.

[14]. Mike LA, Stark AJ, Forsyth VS, et al. A systematic analysis of hypermucoviscosity and capsule reveals distinct and overlapping genes that impact Klebsiella pneumoniae fitness. PLoS Pathog. 2021;17(3):e1009376.

[15]. Xiong H, Carter RA, Leiner IM, et al. Distinct contributions of neutrophils and CCR2+ monocytes to pulmonary clearance of different Klebsiella pneumoniae strains. Infect Immun. 2015;83(9):3418–27.

[16]. Ben-David D, Kordevani R, Keller N, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54–60.

[17]. Tuon FF, Kruger M, Terreri M, et al. Klebsiella ESBL bacteremia-mortality and risk factors. Braz J Infect Dis. 2011;15(6):594–8.

[18]. Deleo FR, Chen L, Porcella SF, et al. Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci U S A. 2014;111(13):4988–93.

[19]. Holt KE, Wertheim H, Zadoks RN, et al. Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proc Natl Acad Sci U S A. 2015;112(27):E3574–81.

[20]. Liang Z, Wang Y, Lai Y, et al. Host defense against the infection of Klebsiella pneumoniae: new strategy to kill the bacterium in the era of antibiotics? Front Cell Infect Microbiol. 2022;12:1050396.

[21]. Ye P, Garvey PB, Zhang P, et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25(3):335–40.

[22]. Xiong H, Keith JW, Samilo DW, et al. Innate Lymphocyte/Ly6C(hi) monocyte crosstalk promotes Klebsiella pneumoniae clearance. Cell. 2016;165(3):679–89.

[23]. Iwanaga N, Chen K, Yang H, et al. Vaccine-driven lung TRM cells provide immunity against Klebsiella via fibroblast IL-17R signaling. Sci Immunol. 2021;6(63):eabf1198.

[24]. Penaloza HF, Noguera LP, Ahn D, et al. Interleukin-10 produced by myeloid-derived suppressor cells provides protection to carbapenem-resistant Klebsiella pneumoniae sequence type 258 by enhancing its clearance in the airways. Infect Immun. 2019;87(5):e00665–18.

[25]. Malachowa N, Kobayashi SD, Porter AR, et al. Vaccine protection against multidrug-resistant Klebsiella pneumoniae in a nonhuman primate model of severe lower respiratory tract infection. mBio. 2019;10(6):e02994–19.

[26]. Schneider DS, Ayres JS. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol. 2008;8(11):889–95.

[27]. Broberg CA, Wu W, Cavalcoli JD, et al. Complete genome sequence of Klebsiella pneumoniae strain ATCC 43816 KPPR1, a rifampin-resistant mutant commonly used in animal, genetic, and molecular biology studies. Genome Announc. 2014;2(5):e00924–14.

[28]. Zheng X, Guo J, Cao C, et al. Time-course transcriptome analysis of lungs from mice infected with hypervirulent Klebsiella pneumoniae via aerosolized intratracheal inoculation. Front Cell Infect Microbiol. 2022;12:833080.

[29]. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8(6):519–30.

[30]. Moldogazieva NT, Mokhosoev IM, Terentiev AA. Metabolic heterogeneity of cancer cells: an interplay between HIF-1, GLUTs, and AMPK. Cancers (Basel). 2020;12(4):862.

[31]. Stine ZE, Schug ZT, Salvino JM, et al. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141–62.

[32]. Traba J, Sack MN, Waldmann TA, et al. Immunometabolism at the nexus of cancer therapeutic efficacy and resistance. Front Immunol. 2021;12:657293.

[33]. OʼNeill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16(9):553–65.

[34]. Kim JW, Tchernyshyov I, Semenza GL, et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–85.

[35]. Hooftman A, Peace CG, Ryan DG, et al. Macrophage fumarate hydratase restrains mtRNA-mediated interferon production. Nature. 2023;615(7952):490–8.

[36]. Kourakis S, Timpani CA, de Haan JB, et al. Dimethyl fumarate and its esters: a drug with broad clinical utility? Pharmaceuticals (Basel). 2020;13(10):306.

[37]. Infantino V, Convertini P, Cucci L, et al. The mitochondrial citrate carrier: a new player in inflammation. Biochem J. 2011;438(3):433–6.

[38]. Peace CG, OʼNeill LA. The role of itaconate in host defense and inflammation. J Clin Invest. 2022;132(2):e148548.

[39]. Jha AK, Huang SC, Sergushichev A, et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity. 2015;42(3):419–30.

[40]. Liu PS, Wang H, Li X, et al. alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017;18(9):985–94.

[41]. Mathis D, Shoelson SE. Immunometabolism: an emerging frontier. Nat Rev Immunol. 2011;11(2):81.

[42]. Mills EL, Ryan DG, Prag HA, et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature. 2018;556(7699):113–7.

[43]. Hooftman A, Angiari S, Hester S, et al. The immunomodulatory metabolite itaconate modifies NLRP3 and inhibits inflammasome activation. Cell Metab. 2020;32(3):468–478.e7.

[44]. Lampropoulou V, Sergushichev A, Bambouskova M, et al. Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation. Cell Metab. 2016;24(1):158–66.

[45]. Tomlinson KL, Riquelme SA, Baskota SU, et al. Staphylococcus aureus stimulates neutrophil itaconate production that suppresses the oxidative burst. Cell Rep. 2023;42(2):112064.

[46]. Yamada KJ, Heim CE, Xi X, et al. Monocyte metabolic reprogramming promotes pro-inflammatory activity and Staphylococcus aureus biofilm clearance. PLoS Pathog. 2020;16(3):e1008354.

[47]. Bhan U, Ballinger MN, Zeng X, et al. Cooperative interactions between TLR4 and TLR9 regulate interleukin 23 and 17 production in a murine model of gram negative bacterial pneumonia. PLoS One. 2010;5(3):e9896.

[48]. Regueiro V, Moranta D, Campos MA, et al. Klebsiella pneumoniae increases the levels of Toll-like receptors 2 and 4 in human airway epithelial cells. Infect Immun. 2009;77(2):714–24.

[49]. Schurr JR, Young E, Byrne P, et al. Central role of toll-like receptor 4 signaling and host defense in experimental pneumonia caused by Gram-negative bacteria. Infect Immun. 2005;73(1):532–45.

[50]. Llobet E, Martinez-Moliner V, Moranta D, et al. Deciphering tissue-induced Klebsiella pneumoniae lipid A structure. Proc Natl Acad Sci U S A. 2015;112(46):E6369–78.

[51]. Ramage B, Erolin R, Held K, et al. Comprehensive arrayed transposon mutant library of Klebsiella pneumoniae outbreak strain KPNIH1. J Bacteriol. 2017;199(20):e00352–17.

[52]. Banerjee S, Zare RN, Tibshirani RJ, et al. Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids. Proc Natl Acad Sci U S A. 2017;114(13):3334–9.

[53]. Dong F, Wang B, Zhang L, et al. Metabolic response to Klebsiella pneumoniae infection in an experimental rat model. PLoS One. 2012;7(11):e51060.

[54]. Al-Khami AA, Zheng L, Del Valle L, et al. Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. Oncoimmunology. 2017;6(10):e1344804.

[55]. Li K, Shi H, Zhang B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362.

[56]. Zhao H, Teng D, Yang L, et al. Myeloid-derived itaconate suppresses cytotoxic CD8(+) T cells and promotes tumour growth. Nat Metab. 2022;4(12):1660–73.

[57]. Weiss JM, Palmieri EM, Gonzalez-Cotto M, et al. Itaconic acid underpins hepatocyte lipid metabolism in non-alcoholic fatty liver disease in male mice. Nat Metab. 2023;5(6):981–95.

[58]. Hossain F, Al-Khami AA, Wyczechowska D, et al. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies. Cancer Immunol Res. 2015;3(11):1236–47.

[59]. Kobayashi SD, Porter AR, Dorward DW, et al. Phagocytosis and killing of carbapenem-resistant ST258 Klebsiella pneumoniae by human neutrophils. J Infect Dis. 2016;213(10):1615–22.

[60]. Domenico P, Salo RJ, Cross AS, et al. Polysaccharide capsule-mediated resistance to opsonophagocytosis in Klebsiella pneumoniae. Infect Immun. 1994;62(10):4495–9.

[61]. Broug-Holub E, Toews GB, van Iwaarden JF, et al. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun. 1997;65(4):1139–46.

[62]. Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485–98.

[63]. Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity. Immunity. 2021;54(5):875–84.

[64]. Arora M, Poe SL, Oriss TB, et al. TLR4/MyD88-induced CD11b+Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. Mucosal Immunol. 2010;3(6):578–93.

[65]. Poe SL, Arora M, Oriss TB, et al. STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. Mucosal Immunol. 2013;6(1):189–99.

[66]. Weiss JM, Davies LC, Karwan M, et al. Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors. J Clin Invest. 2018;128(9):3794–805.

[67]. Qin W, Qin K, Zhang Y, et al. S-glycosylation-based cysteine profiling reveals regulation of glycolysis by itaconate. Nat Chem Biol. 2019;15(10):983–91.

[68]. Swain A, Bambouskova M, Kim H, et al. Comparative evaluation of itaconate and its derivatives reveals divergent inflammasome and type I interferon regulation in macrophages. Nat Metab. 2020;2(7):594–602.

[69]. Chen LL, Morcelle C, Cheng ZL, et al. Itaconate inhibits TET DNA dioxygenases to dampen inflammatory responses. Nat Cell Biol. 2022;24(3):353–63.

[70]. Liu D, Xiao W, Li H, et al. Discovery of itaconate-mediated lysine acylation. J Am Chem Soc. 2023;145(23):12673–81.

[71]. McFadden BA, Purohit S. Itaconate, an isocitrate lyase-directed inhibitor in Pseudomonas indigofera. J Bacteriol. 1977;131(1):136–44.

[72]. Zhang Y, Qin W, Liu D, et al. Chemoproteomic profiling of itaconations in Salmonella. Chem Sci. 2021;12(17):6059–63.

[73]. Riquelme SA, Liimatta K, Wong Fok Lung T, et al. Pseudomonas aeruginosa utilizes host-derived itaconate to redirect its metabolism to promote biofilm formation. Cell Metab. 2020;31(6):1091–1106.e6.

[74]. Tomlinson KL, Wong Fok Lung T, Dach F, et al. Staphylococcus aureus induces an itaconate-dominated immunometabolic response that drives biofilm formation. Nat Commun. 2021;12(1):1399.

[75]. Zoued A, Brunet YR, Durand E, et al. Architecture and assembly of the Type VI secretion system. Biochim Biophys Acta. 2014;1843(8):1664–73.

[76]. Monjaras Feria J, Valvano MA. An overview of anti-eukaryotic T6SS effectors. Front Cell Infect Microbiol. 2020;10:584751.

[77]. Si M, Zhao C, Burkinshaw B, et al. Manganese scavenging and oxidative stress response mediated by type VI secretion system in Burkholderia thailandensis. Proc Natl Acad Sci U S A. 2017;114(11):E2233–42.

[78]. Wang T, Si M, Song Y, et al. Type VI secretion system transports Zn2+ to combat multiple stresses and host immunity. PLoS Pathog. 2015;11(7):e1005020.

[79]. Wan B, Zhang Q, Ni J, et al. Type VI secretion system contributes to Enterohemorrhagic Escherichia coli virulence by secreting catalase against host reactive oxygen species (ROS). PLoS Pathog. 2017;13(3):e1006246.

[80]. Yu KW, Xue P, Fu Y, et al. T6SS mediated stress responses for bacterial environmental survival and host adaptation. Int J Mol Sci . 2021;22(2):478.

[81]. OʼDwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol. 2016;196(12):4839–47.

[82]. Sa-Pessoa J, Lopez-Montesino S, Przybyszewska K, et al. A trans-kingdom T6SS effector induces the fragmentation of the mitochondrial network and activates innate immune receptor NLRX1 to promote infection. Nat Commun. 2023;14(1):871.

[83]. Ahn D, Bhushan G, McConville TH, et al. An acquired acyltransferase promotes Klebsiella pneumoniae ST258 respiratory infection. Cell Rep. 2021;35(9):109196.

[84]. Cesur MF, Siraj B, Uddin R, et al. Network-based metabolism-centered screening of potential drug targets in Klebsiella pneumoniae at genome scale. Front Cell Infect Microbiol. 2019;9:447.

[85]. Heim CE, Bosch ME, Yamada KJ, et al. Lactate production by Staphylococcus aureus biofilm inhibits HDAC11 to reprogramme the host immune response during persistent infection. Nat Microbiol. 2020;5(10):1271–84.

[86]. Hawkey J, Vezina B, Monk JM, et al. A curated collection of Klebsiella metabolic models reveals variable substrate usage and gene essentiality. Genome Res. 2022;32(5):1004–14.

[87]. Lan P, Jiang Y, Zhou J, et al. A global perspective on the convergence of hypervirulence and carbapenem resistance in Klebsiella pneumoniae. J Glob Antimicrob Resist. 2021;25:26–34.

[88]. Kochan TJ, Nozick SH, Medernach RL, et al. Genomic surveillance for multidrug-resistant or hypervirulent Klebsiella pneumoniae among United States bloodstream isolates. BMC Infect Dis. 2022;22(1):603.

[89]. Liu C, Du P, Yang P, et al. Emergence of extensively drug-resistant and hypervirulent KL2-ST65 Klebsiella pneumoniae harboring bla(KPC-3) in Beijing, China. Microbiol Spectr. 2022;10(6):e0304422.

[90]. Dong N, Yang X, Chan EW, et al. Klebsiella species: taxonomy, hypervirulence and multidrug resistance. EBioMedicine. 2022;79:103998.

引用本文

Prince, Alice; Wong Fok Lung, Tania. Immunometabolic control by Klebsiella pneumoniae [J]. Immunometabolism. 2023; 5; (3). 1 - 9.

文献评论

刘**南昌大学****** 已认证✔

2025-11-24 11:25:45

这篇文章不错

相关学者

相关机构